Key Moments
Harvard Thinking: The healing power of gene therapy
Harvard UniversityKey Moments
Gene therapy can now cure previously untreatable genetic disorders and restore hearing, but economic and regulatory hurdles make widespread access a massive challenge.
Key Insights
The first child treated with base editing, KJ, was cured of a fatal genetic disorder (CPS1 deficiency) in under seven months from concept to treatment.
Over 200,000 known mutations in human DNA cause more than 8,000 genetic diseases, many of which are serious or fatal.
The FDA-approved gene therapy for hearing loss, Otarmeni, uses an Adeno-Associated Virus (AAV) to deliver a functional copy of the otoferlin gene.
The cost of developing gene therapies can run into millions or tens of millions of dollars, making treatments for rare diseases financially unsustainable for a single patient.
AI is increasingly used in gene therapy research for tasks like literature review, data analysis, and designing novel proteins with therapeutic potential.
While gene therapy is not currently legal for germline cells (sperm/eggs), the potential for hereditary disease prevention raises complex ethical questions.
A child's life-saving treatment showcases gene editing's potential
The transcript highlights the groundbreaking case of KJ, a child born with a fatal genetic disorder called CPS1 deficiency. Through a rapid, coordinated effort, researchers developed a personalized base editing therapy that corrected a specific mutation in his DNA. This intervention, completed in under seven months from concept to treatment, resulted in KJ’s complete recovery, allowing him to grow and develop normally. This success demonstrates the profound impact of gene editing technologies, showcasing that individuals are not necessarily 'hostages to their gene errors.' The speed and efficacy of this treatment underscore the transformative potential of gene therapy to address previously incurable conditions.
Understanding gene editing and gene replacement therapies
Gene editing, a precise form of gene therapy, involves directly altering a patient's DNA to correct harmful mutations. David Liu explains that techniques like base editing and prime editing allow for targeted changes to specific DNA sequences. For instance, KJ's therapy corrected an 'A' to a 'G' nucleotide. Gene replacement therapy, as practiced by Eliot Shear, involves introducing a functional copy of a gene into the body, often using viral vectors like Adeno-Associated Viruses (AAVs). This approach is suitable for diseases where the gene is missing or non-functional. The choice between gene editing and gene replacement depends heavily on the specific disease and target.
Gene therapy for hearing loss: a new frontier
Eliot Shear discusses the development of gene therapies for hearing loss, a condition with significant genetic heterogeneity, caused by over 150 different genes and thousands of mutations. While cochlear implants have been a successful neural replacement for decades, offering near-normal speech and language development, gene therapy aims to restore hearing at a more fundamental level. The recent FDA-approved therapy, Otarmeni, targets mutations in the otoferlin gene, essential for auditory nerve function. It uses a safe AAV vector to deliver a functional copy of the gene directly to the cochlea, a complex surgical procedure. This represents a significant advancement towards treating the genetic roots of hearing loss.
The economic and regulatory hurdles to widespread access
A major challenge in gene therapy is its immense cost. Developing personalized therapies for rare diseases, like KJ's case, can cost millions to tens of millions of dollars, making it financially unsustainable if only a few patients can benefit. David Liu points out that while gene therapies for conditions like sickle cell disease, which affect thousands, can be economically viable, the economics become difficult for ultra-rare disorders. This financial reality has led to the establishment of non-profit initiatives like the Center for Gene Therapy (CTG) to address these diseases where the industry cannot. Regulatory processes, while crucial for safety, also add significant time and expense to development, though regulators are seen as partners rather than adversaries.
Ethical considerations: playing God vs. alleviating suffering
The conversation touches upon the philosophical debate of 'playing God' with gene therapy. Eliot Shear emphasizes respecting patient autonomy, noting that not all families view hearing loss as a disability, and respects their choices. He clarifies that gene replacement therapy does not alter a patient's germline. David Liu acknowledges the ethical complexities, particularly concerning potential disease prevention versus treating severe, life-threatening conditions. While treating debilitating diseases like sickle cell anemia or infant metabolic disorders is widely accepted, the ethics of altering genes for disease prevention (e.g., reducing Alzheimer's risk) or for traits considered non-pathological (like deafness) are more contentious. Ultimately, he views using gene therapy to cure severe diseases as a unique human capability that does not compromise our humanity, provided it's done responsibly.
The role of artificial intelligence in advancing gene therapy
Both researchers highlight the increasing integration of Artificial Intelligence (AI) in their labs. AI is used for routine tasks like literature review and data analysis, as well as for more complex innovations. David Liu mentions using AI to design novel proteins with therapeutic functions that are more stable than natural ones, citing a Nature publication showcasing this capability. Eliot Shear notes AI's critical role in identifying whether genetic variants are pathogenic, which is crucial for diagnosing conditions like hearing loss and determining eligibility for gene therapy. This suggests AI is becoming an indispensable tool in accelerating gene therapy research and development.
The future of genetic medicine: diagnosis and accessibility
Looking ahead, both experts stress the importance of improved genetic diagnostics. Currently, less than half of children with potential inherited hearing loss receive genetic testing. The dramatic decrease in DNA sequencing costs makes widespread genetic screening more feasible. In the next 5-10 years, they envision a future where patients arrive with a genetic diagnosis, and clinicians can select the most appropriate gene therapy from a range of options. They anticipate that as gene therapies become more common and effective, previously undiagnosed conditions will be identified, further driving the development of new treatments and compensatory mechanisms to ensure equitable access.
Mentioned in This Episode
●Companies
●Organizations
●Books
●Drugs & Medications
●Concepts
●People Referenced
Gene Therapy: Key Considerations
Practical takeaways from this episode
Do This
Avoid This
Common Questions
Gene therapy involves introducing a functional gene copy into the body to treat diseases caused by genetic mutations. There are different approaches, including gene editing (like base editing) to correct specific mutations and gene replacement therapy using viral vectors to deliver healthy genes.
Topics
Mentioned in this video
The U.S. Food and Drug Administration, which approved the clinical trial for KJ's treatment and later approved the first gene therapy for hearing loss.
An institute where David Liu is a professor, involved in gene editing research.
A non-profit organization collaborating with the Broad Institute and Boston Children's Hospital on the Centralized Therapeutic Genetics (CTG).
An institute where David Liu is a professor, involved in gene editing research.
Medical school where Elliot Scher is an associate professor.
A hospital where Elliot Scher works as a pediatric ENT and performs gene therapy surgeries for hearing loss.
University where Dr. Kiera Musenor from the team that treated KJ is based.
A non-profit center co-founded by David Liu to address rare genetic diseases where industry may not develop treatments due to economic reasons.
The first gene editing therapy approved by the FDA, which reactivates fetal hemoglobin genes to compensate for adult hemoglobin mutations.
An FDA-approved gene therapy for hearing loss developed by Regeneron, which uses an adeno-associated virus to deliver a functional copy of the otoferlin gene.
Professor at Harvard University, the Broad Institute, and the Howard Hughes Medical Institute, developing and applying gene editing technologies.
Host of the 'Harvard Thinking' podcast and writer for The Harvard Gazette.
Pediatric ENT at Boston Children's Hospital and Associate Professor at Harvard Medical School, performing gene therapy surgery for children with hearing loss.
More from Harvard University
View all 24 summaries
138 minHarvard Alumni Day 2026
25 minLt. Gen. (Ret.) Richard Clark Keynote Address | 2026 ROTC Commissioning
228 minHarvard Commencement 2026
22 minRonny Chieng Address | Harvard Class Day 2026
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free